Urteste

Urteste EBIT CAGR 5Y

The EBIT CAGR (5 Year) of Urteste (URT.WA) as of Nov 1, 2026 is 47.48 %. In the previous year, EBIT CAGR (5 Year) was 47.48 % — a change of 0.00% (lower).

EBIT CAGR 5Y

47.48 %

YoY

0.00%

Last updated:

EBIT CAGR (5 Year) of Urteste is 2025 47.48 % . EBIT CAGR (5 Year) of Urteste was 2024 47.48 % . It decreases by 0.00% lower compared to the previous year.

The Urteste EBIT CAGR 5Y history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT CAGR 5Y
Date
EBIT CAGR 5Y
Jan 1, 2019
47.48 PLN
Jan 1, 2020
47.48 PLN
Jan 1, 2021
47.48 PLN
Jan 1, 2022
47.48 PLN
Jan 1, 2023
47.48 PLN
Jan 1, 2024
47.48 PLN
Jan 1, 2025
47.48 PLN
The Urteste EBIT CAGR 5Y history
YEAREBIT CAGR 5YYoY
47.48 %0.00%
47.48 %0.00%
47.48 %0.00%
47.48 %0.00%
47.48 %0.00%
47.48 %0.00%
47.48 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Urteste Stock analysis

What does Urteste do? Urteste SA develops technology for early cancer detection through urine-based enzyme activity measurement, offering diagnostic tests for multiple cancers including pancreatic, prostate, colorectal, lung, kidney, liver, biliary tract, stomach, esophageal, ovarian, endometrial, breast, leukemia, lymphoma, and glioma. The company operates in the medical devices sector for in vitro diagnostics, targeting healthcare providers and diagnostic laboratories that require early-stage cancer screening solutions. Its products enable non-invasive testing for common cancers, providing a competitive advantage in early detection markets. Urteste SA's business model focuses on selling diagnostic kits and test services directly to hospitals and specialized medical facilities. The firm's technology differentiates itself by analyzing enzyme activity in urine samples, allowing for the detection of various cancers without invasive procedures. This approach appeals to healthcare institutions seeking efficient, cost-effective screening methods for high-risk patient populations. Urteste SA's product portfolio includes specific tests for each listed cancer type, catering to the growing demand for early cancer diagnostics in clinical settings. The company's revenue streams derive from the sale of diagnostic kits and associated testing services to medical facilities that implement these tests in their screening protocols. Urteste SA's target market consists of hospitals, diagnostic laboratories, and specialized medical centers that prioritize early cancer detection as part of their patient care strategies. These institutions purchase the company's diagnostic tests to enhance their screening capabilities and improve patient outcomes through timely interventions. The firm's offerings address the specific needs of healthcare providers looking for reliable, non-invasive methods to detect multiple cancer types simultaneously. By focusing on urinary enzyme analysis, Urteste SA positions itself as a key provider of innovative diagnostic solutions in the cancer screening market. Urteste is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Urteste stock

EBIT CAGR (5 Year) of Urteste is 47.48 % in 2025.

On Eulerpool you can find the complete historical development of EBIT CAGR (5 Year) Urteste since 2006 – with annual values, charts, and detailed analysis.

The 5-year EBIT CAGR shows the compound annual growth rate of EBIT over the past five years.

To evaluate EBIT CAGR (5 Year)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT CAGR (5 Year).

EBIT CAGR (5 Year)'s is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT CAGR (5 Year)'s Urteste historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Urteste

All Key Metrics — Urteste